story

Catalym

CatalYm GmbH develops innovative immunotherapies that activate the body’s immune system to fight cancer, aiming to improve treatment outcomes and transform the lives of patients worldwide.

Biotech, Germany


About Catalym

Founded in 2016, Catalym is a biotechnology company focused on developing innovative cancer immunotherapies that harness the body’s own immune system to fight tumors. The company specializes in creating antibodies that target a placental factor overexpressed in various cancer types, which plays a key role in suppressing immune responses. By neutralizing this factor, Catalym aims to restore and activate the patient’s immune system to recognize and attack cancer cells more effectively, advancing new treatment options in immuno-oncology.

Legal Name

: Catalym

Headquarters

: Munich, Bayern, Germany

Business Model

: B2B, B2C

Founding Date

: 2016

No. of Employees

: 11-50

Founding Members

: 1. Scott Clarke CEO


Recently Added Startups